Recently, small-cap biotech and pharma tickers have experienced a sharp sell-off, which caused a few watch list tickers pop-up on my scanners for a possible buying opportunity. I was surprised to see Sesen Bio (SESN) was one of those discounted tickers considering they are in the process of a rolling BLA for their Vicinium product candidate. If approved, this $93M market-cap biotech should experience a sharp increase in buying as the market begins to realize Vicinium’s commercial prospects.
Figure 1: SESN Daily (Source: Trendspider)
Vicinium has exceptional Phase III data and